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ABSTRACT
Background. In patients with metastatic colorectal cancer
(mCRC) with an asymptomatic primary tumor, there is no
consensus on the indication for resection of the primary
tumor.
Methods. A retrospective analysis was performed on the
outcome of stage IV colorectal cancer (CRC) patients with
or without resection of the primary tumor treated in the
phase III CAIRO and CAIRO2 studies. A review of the
literature was performed.
Results. In the CAIRO and CAIRO2 studies, 258 and 289
patients had undergone a primary tumor resection and 141
and 159 patients had not, respectively. In the CAIRO study,
a signiﬁcantly better median overall survival and progres-
sion-free survival was observed for the resection compared
to the nonresection group, with 16.7 vs. 11.4 months
[P\0.0001, hazard ratio (HR) 0.61], and 6.7 vs.
5.9 months (P = 0.004; HR 0.74), respectively. In the
CAIRO2 study, median overall survival and progression-
free survival were also signiﬁcantly better for the resection
compared to the nonresection group, with 20.7 vs.
13.4 months (P\0.0001; HR 0.65) and 10.5 vs.
7.8 months (P = 0.014; HR 0.78), respectively. These
differences remained signiﬁcant in multivariate analyses.
Our review identiﬁed 22 nonrandomized studies, most of
which showed improved survival for mCRC patients who
underwent resection of the primary tumor.
Conclusions. Our results as well as data from literature
indicate that resection of the primary tumor is a prognostic
factor for survival in stage IV CRC patients. The potential
bias of these results warrants prospective studies on the
value of resection of primary tumor in this setting; such
studies are currently being planned.
For most patients with metastatic colorectal cancer
(mCRC), there are no curative options, but a beneﬁt in
median overall survival (OS) can be achieved with pallia-
tive systemic treatment.
1 This treatment currently consists
of cytotoxic chemotherapy and targeted therapy. The
5-year OS for patients who are diagnosed with distant
metastases ranges 10–20%.
2–4 The median OS is improved
when patients are exposed to all available cytotoxic drugs
during the course of their disease.
5 Because the disease of
only a subset of patients will respond to systemic treat-
ment, we need predictive and prognostic markers that will
permit us to select patients who may experience the
 The Author(s) 2011. This article is published with open access
at Springerlink.com
First Received: 17 January 2011;
Published Online: 6 August 2011
M. Koopman, MD, PhD
e-mail: M.Koopman-6@umcutrecht.nl
Ann Surg Oncol (2011) 18:3252–3260
DOI 10.1245/s10434-011-1951-5optimal beneﬁt of available treatments. Currently available
biomarkers are not predictive for the efﬁcacy of chemo-
therapy, and for targeted therapy, only KRAS mutation
status is predictive for response to anti–epidermal growth
factor receptor therapy, with BRAF mutation status being a
candidate prognostic marker.
6–8
Patients with colorectal cancer (CRC) with stage IV
disease may manifest various symptoms of their primary
tumor and/or metastases, and a palliative resection of the
primary tumor before the initiation of systemic treatment is
frequently performed.
9 This indication is obvious in
patients with a symptomatic primary. However, in patients
with few or absent symptoms, the indication for resection is
under debate, and its effect on survival and quality of life is
still uncertain.
10–12 The possible inﬂuence of a palliative
resection of the primary tumor on survival has never been
properly assessed, and most randomized studies in mCRC
do not even report whether a resection of the primary tumor
has been performed.
13,14
We here report a retrospective analysis of two phase III
studies on the prognostic and predictive value of resection
of the primary tumor in stage IV mCRC patients.
15,16 Data
on the toxicity of systemic treatment in resected versus
nonresected patients are presented. We review the litera-
ture on this issue and discuss our data in relation to the
results of this review.
METHODS
CAIRO Studies
Data of metastatic CRC patients included in two phase
III studies (CAIRO and CAIRO2) of the Dutch Colo-
rectal Cancer Group were used (ClinicalTrials.gov
NCT00312000 and NCT00208546). Details of these stud-
ies have been published elsewhere.
15–18
Patients with stage IV disease (metastatic disease at
diagnosis) were classiﬁed as having undergone a resection
(resection group) or no resection (nonresection group) of
the primary tumor before randomization in the study.
Patients who had undergone a resection of the primary
tumor after randomization and patients who had an
incomplete resection of the primary tumor before ran-
domization were included in the nonresection group. To
assess the prognostic value of resection, we analyzed the
total group of patients in each study with stage IV disease
and compared the outcome of the resection group with the
nonresection group. To assess the predictive value of
resection, we analyzed the interaction of resection with the
outcome of ﬁrst-line treatment per treatment arm in each
study. Toxicity was scored according to U.S. National
Cancer Institute Common Toxicity Criteria, version 2.0.
Statistical Methods
Ineligible patients were excluded from the analysis. The
progression-free survival (PFS) was calculated from the
date of randomization to the ﬁrst observation of disease
progression or death from any cause. OS and PFS curves
were estimated by the Kaplan-Meier method and compared
by the log rank test. Multivariate analysis of survival was
performed by the Cox proportional hazard model. The
comparison of factors between groups (resection vs. non-
resection) was performed by chi-square, Fisher’s exact, or
Mann-Whitney tests, where appropriate. All tests were
two-sided, and P values of less than 0.05 were considered
statistically signiﬁcant. All analyses were performed by
SAS 9.1 and S-plus 6.2 software.
Literature Search Strategy, Inclusion Criteria,
and Data Extraction
We reviewed the literature on the prognostic and/or
predictive value of resection of the primary tumor in
mCRC patients with unresectable distant metastases. The
primary outcomes of interest were OS, toxicity, and mor-
bidity. A search was conducted of Medline, PubMed, and
the Cochrane Library from January 1980 to December
2010 with an English-language restriction.
Original publications were selected if the abstract con-
tained safety and efﬁcacy data for patients with and without
resection of the primary tumor. In case of duplicate pub-
lications, the most recent and/or most complete study was
included. We excluded cohorts of patients with mCRC who
were candidates for potentially curative metastasectomy,
and publications that included only rectal cancer or merely
focused on the surgical procedure.
RESULTS
CAIRO Study
Patient Characteristics Of the 803 eligible patients with
advanced CRC disease in the CAIRO study, 399 patients
had stage IV disease at inclusion. Of these patients, 258
were placed in the resection group and 141 patients in the
nonresection group. Patients in the nonresection group
more often had abnormal baseline serum lactate
dehydrogenase (LDH), more often had predominant
extrahepatic metastases, more often had a primary tumor
located in rectosigmoid or rectum, and received fewer
cycles of chemotherapy (Table 1). At baseline, none of the
patients had grade 3–4 nausea, vomiting, or ileus toxicity.
Only two patients in the nonresection group had grade 3–4
diarrhea toxicity at presentation (P = 0.06).
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signiﬁcantly better median OS and PFS was observed for
patients in the resection versus the nonresection group, with
16.7 vs. 11.4 months [P\0.0001; hazard ratio (HR) 0.61,
95%conﬁdenceinterval(CI)0.49–0.76](Fig. 1),and6.7vs.
5.9 months (P = 0.004; HR 0.74, 95% CI 0.60–0.91),
respectively. A multivariate analysis was performed that
included baseline serum LDH, predominant localization of
metastases, performance status, localization of the primary
tumor, and chemotherapy schedule. Resection of the
primary tumor was prognostic for OS and borderline
prognostic for PFS in patients with only one metastatic
site (P = 0.016, HR 0.63, 95% CI 0.43–0.92, and P =
0.069, HR 0.57, 95% CI 0.30–1.25), but not in patients with
two or more metastatic sites (P = 0.276, HR 0.88, 95% CI
0.70–1.11, and P = 0.444, HR 1.10, 95% CI 0.87–1.38).
Predictive Value of Resection of the Primary Tumor The
primary objective of the CAIRO study was to evaluate
sequentialversuscombinationchemotherapy.Nosigniﬁcant
interaction with sequential versus combination treatment in
respect to median OS was observed for patients in the
resection group (16.2, 95% CI 13.5–29.4 vs. 17.6 months,
95% CI 14.8–20.1) and the nonresection group (9.8, 95% CI
7.9–11.8, vs. 14.9 months, 95% CI 10.8–16.4) (P = 0.769).
Toxicity We assessed a possible interaction for patient
symptoms that may have been related to the presence of the
primary tumor—that is, nausea, vomiting, ileus, diarrhea,
and fatigue.
In ﬁrst-line treatment, none of the instances of grade 3–4
toxicity occurred signiﬁcantly more frequently in the
nonresection group compared to the resection group. When
all treatment lines were considered, the incidence of grade
3–4 vomiting and ileus in the overall study population
occurred signiﬁcantly more frequently in the nonresection
compared to the resection group, with 11% vs. 5% for
vomiting (P = 0.053) and 7% vs. 2% for ileus
(P = 0.019), respectively. In the sequential treatment arm,
nausea and fatigue occurred signiﬁcantly more frequently
in the nonresection compared to the resection group; 13%
vs. 5% (P = 0.054) and 33% vs. 18% (P = 0.014),
respectively. In the combination treatment arm, only grade
3–4 ileus occurred signiﬁcantly more frequently in the
TABLE 1 Characteristics of 399 stage IV CRC patients on the
CAIRO study with resection and nonresection of primary tumor
Characteristic Resection
group
(n = 258)
Nonresection
group (n = 141)
P value
Sex 0.086
Male 159 (62%) 99 (70%)
Female 99 (38%) 42 (30%)
Age, years 0.138
Median 63 60
Range 34–81 27–82
LDH serum \0.0001
Normal 164 (64%) 49 (35%)
Abnormal 94 (36%) 92 (65%)
Performance status 0.382
0 161 (62%) 78 (55%)
1 84 (33%) 55 (39%)
2 13 (5%) 8 (6%)
Predominant
localization of
metastases
0.005
Liver 233 (81%) 113 (81%)
Extrahepatic 23 (9%) 26 (19%)
Localization of the
primary tumor
0.005
Colon 183 (71%) 78 (55%)
Rectosigmoid 16 (6%) 15 (11%)
Rectum 56 (22%) 48 (34%)
Multiple tumor 3 (1%) 0 (0%)
Metastatic sites
involved
0.067
1 119 (46%) 50 (36%)
[2 137 (53%) 90 (64%)
Unknown 2 (1%) 0 (0%)
Treatment arm 0.517
Sequential 123 (48%) 72 (51%)
Combination 135 (52%) 69 (49%)
No. of cycles 0.004
Median (range) 8 (0–53) 6 (0–18)
FIG. 1 OS (months) for resection vs. nonresection of the primary
tumor in the CAIRO study
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(P = 0.029).
CAIRO2 Study
Patient Characteristics Of the 736 eligible mCRC
patients in the CAIRO2 study, 448 patients had stage IV
disease at inclusion. Of these patients, 289 were assigned to
the resection group and 159 patients to the nonresection
group. Patients in the nonresection group were more often
men, were younger, more often had abnormal baseline
serum LDH, had a worse performance status, and more
often had liver plus other metastases and a larger number of
metastatic sites compared to the resection group (Table 2).
At baseline, none of the patients presented with grade 3–4
nausea, vomiting, or ileus toxicity. Only one patient in the
nonresection group had grade 3–4 diarrhea toxicity at
presentation (P = 0.178).
Prognostic Value of Resection of the Primary Tumor A
signiﬁcantly better median OS and PFS were observed for
patients in the resection versus the nonresection group,
with 20.7 vs. 13.4 months (P\0.0001; HR 0.65, 95% CI
0.52–0.80) (Fig. 2), and 10.5 vs. 7.8 months (P = 0.015;
HR 0.78, 95% CI 0.64–0.95), respectively.
In the multivariate analysis that included sex, age,
baseline serum LDH, performance status, localization of
metastases, localization of primary tumor, number of
metastatic sites involved, and treatment arm, resection of
the primary tumor remained an independent prognostic
factor for median OS (P = 0.010; HR 0.73, 95% CI
0.58–0.93), but not for PFS (P = 0.130; HR 0.84, 95% CI
0.68–1.05).
Predictive Value of Resection of the Primary Tumor The
primary objective of the CAIRO2 study was to evaluate the
addition of cetuximab to capecitabine, oxaliplatin, and
bevacizumab. No signiﬁcant interaction with treatment was
observedinrespecttomedianOSforpatientsintheresection
group (21.6, 95% CI 17.6–27.8 vs. 20.2 months, 95% CI
17.1–22.2) and the nonresection group (13.4, 95% CI
11.7–18.4vs.13.8 months,95%CI10.9–17.8)(P = 0.612).
Toxicity
We assessed a possible interaction for patient symptoms
that may have been related to the presence of the primary
tumor—that is, nausea, vomiting, ileus, diarrhea, and
fatigue.
For the overall study population, grade 3–4 nausea,
vomiting, ileus, and fatigue toxicity occurred signiﬁcantly
more frequently in the nonresection compared to the
resection group, 9% vs. 3% for nausea (P = 0.004), 9% vs.
4% for vomiting (P = 0.043), 8% vs. 3% for ileus
(P = 0.019), and 23% vs. 13% for fatigue (P = 0.004),
respectively.
In the treatment arm without cetuximab, grade 3–4
nausea, vomiting, and fatigue occurred signiﬁcantly more
frequently in the nonresection group compared to the
resection group, 13% vs. 4% for nausea (P = 0.015), 15%
vs. 4% for vomiting (P = 0.003), and 21% vs. 11%
(P = 0.046) for fatigue, respectively. In the treatment arm
with cetuximab, only grade 3–4 fatigue occurred signiﬁ-
cantly more frequently in the nonresection group compared
to the resection group; 25% vs. 14% (P = 0.042).
TABLE 2 Characteristics of 488 stage IV CRC patients on the
CAIRO2 study with resection and nonresection of primary tumor
Characteristic Resection group
(n = 289)
Nonresection
group (n = 159)
P value
Sex 0.011
Male 155 (54%) 105 (66%)
Female 134 (46%) 54 (34%)
Age, years 0.008
Median 62.2 59.5
Range 34.7–80.0 31.4–77.7
LDH serum \0.0001
Normal 172 (60%) 44 (28%)
Abnormal 115 (40%) 115 (72%)
Performance status 0.001
0 184 (64%) 76 (48%)
1 104 (36%) 83 (52%)
Localization of
metastases
0.001
Liver 114 (39%) 51 (32%)
Liver ? other 138 (48%) 99 (62%)
Extrahepatic 34 (12%) 4 (3%)
Locally advanced 0 (0%) 2 (1%)
Unknown 3 (1%) 3 (2%)
Localization of
primary tumor
0.121
Colon 128 (51%) 71 (48%)
Rectosigmoid 76 (31%) 37 (25%)
Rectum 45 (18%) 39 (27%)
Metastatic sites
involved
0.011
1 132 (46%) 52 (34%)
[2 153 (54%) 102 (66%)
Treatment arm 0.787
CB 142 (49%) 76 (48%)
CBC 147 (51%) 83 (52%)
No. of cycles 0.410
Median (range) 9 (0–76) 9 (1–52)
CB chemotherapy ? bevacizumab (arm A), CBC chemother-
apy ? bevacizumab ? cetuximab (arm B)
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The literature search identiﬁed 22 nonrandomized, sin-
gle-center studies (Tables 3 and 4). Twenty-one studies
were retrospective, and one study concerned a case-mat-
ched cohort analysis.
13,19–39 Two studies were restricted to
patients without symptoms of their primary tumor.
23,25
Deﬁnition of nonresection was deﬁned either as surgical
intervention without resection (group 1; 12 studies;
Table 3) or as no surgical intervention (group 2; 12 studies;
Table 4). In both groups, resection was deﬁned as a
resection of the primary tumor. Two studies used both
deﬁnitions for nonresection, and therefore we present the
results of these studies in the analysis of both groups.
24,29
In group 1, the median OS was statistically signiﬁcantly
better in resected versus nonresected patients in 8 of 12
studies.
13,19,21,27,28,35,37,38 The conclusion of most of these
studies was that resection should be performed if feasible,
in particular in symptomatic patients (Table 3).
13,21,27,29,
30,32,35,37 Two studies presented a subgroup analysis in
asymptomatic patients, and although patients who under-
went resection had a signiﬁcantly better median OS
compared to patients without resection, both studies sug-
gested that nonresection of the primary tumor is a valid
treatment choice in this setting.
35,37 This was supported in
one study by a multivariate analysis that identiﬁed che-
motherapy as the only prognostic factor for OS in
asymptomatic patients, and in the other by the fact that the
advantages of primary tumor resection in asymptomatic
patients are outweighed by perioperative mortality.
35,37
The postoperative mortality was higher in the nonresection
group (0–36%) compared to the resection group (3–16%)
in 5 of 12 studies. The incidence of postoperative
morbidity ranged 3–50% in the resection group versus
0–38% in the nonresection group.
In group 2, 6 of 12 studies demonstrated an improved
median OS in the resection compared to the nonresection
group (Table 4).
20,22,25,26,29,33 In three studies a subset of
patients was reported to be asymptomatic in relation to
their primary tumor,
33,34,39 of which the largest study
showed a signiﬁcant beneﬁt in OS for patients with a
resection of the primary tumor.
33 The postoperative mor-
tality ranged 0–16%, and the postoperative morbidity
ranged 10–34.7% (Table 4). In 8 of 12 studies, both the
resected and nonresected groups received chemother-
apy.
20,22,23,25,26,31,36,39 Tebbutt et al.
36 suggested that most
patients who do not require surgical intervention for
complications of their primary tumor at the time of diag-
nosis can be safely treated with chemotherapy because no
increase of intestinal complications was observed.
DISCUSSION
To our knowledge, this is the ﬁrst retrospective analysis
of two phase III studies investigating the prognostic and
predictive value of resection of the primary tumor in
patients with stage IV CRC treated with systemic therapy.
We identiﬁed resection of the primary tumor as a prog-
nostic factor for OS. Resection was not predictive in
relation to the outcome of treatment that was used in these
studies. We observed a higher incidence of toxicity in the
nonresected group, in particular in the CAIRO2 study.
It seems plausible that a resection was performed or at
least attempted in patients who had symptoms that
demanded urgent surgical treatment. However, a major
limitation of our study is that the decision to resect the
primary tumor was made before study entry, and thus we
have no information about the reasons for nonresection,
such as irresectability of the primary tumor, poor condition
of the patient, symptomatic metastases requiring priority
for systemic treatment, or absence of symptoms of the
primary tumor. Obviously, these concern arguments of a
highly different nature and may deﬁne different patient
populations. For instance, the fact that patients in the
nonresection group more often had an elevated serum LDH
and a larger number of metastatic sites may have shifted
the decision of the treating physician toward nonresection.
However, when these variables were included in a multi-
variate analysis, resection of the primary tumor remained a
prognostic factor in the CAIRO2 study and in the subgroup
of patients with one metastatic site in the CAIRO study.
What can we learn from our review on this subject? The
studies that we identiﬁed were of nonrandomized design,
performed in a single center, and retrospective of nature,
with only one exception. Taken together, the data were in
FIG. 2 OS (months) for resection vs. nonresection of the primary
tumor in the CAIRO2 study
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symptomatic lesions. In asymptomatic patients, the results
are less clear, although the median OS was improved in
resected patients in most studies. An important limitation
of these studies is that few if any data on the use of sys-
temic therapy were presented, which, given its impact on
survival, makes it difﬁcult to assess the relative contribu-
tion of resection to outcome.
The two main objectives in the management of patients
with irresectable mCRC are to improve or maintain the
quality of life and to prolong survival. The treatment
strategy in patients with stage IV disease and a symptom-
atic primary tumor usually consists of initial resection of
this tumor, followed by palliative systemic treatment. In
patients with few or absent symptoms of the primary
tumor, arguments both in favor and against initial resection
have been presented. The most dominant argument in favor
of initial resection is the prevention of complications of the
primary tumor with subsequent prolongation of symptom-
free survival and OS.
29,40,41 Furthermore, Stillwell et al.
TABLE 3 Studies in which resection was deﬁned as resection of the primary tumor and nonresection was deﬁned as surgical intervention
without resection (i.e., enterostomy, bypass, stenting)
Author Years of
study
Resection No. of
patients
OS
(months)
P value Postoperative
mortality (%)
P value Morbidity
(%)
P value Chemotherapy
(%)
Makela et al.
30a 1974–1983 Resection 66 15 NA 5 – 24 – In total 22
Nonresection 30 7 17 23
Liu et al.
29a 1986–1991 Resection 57 11 NA 9 – 10 – –
Nonresection 6 3 17 NA
Konyalian
et al.
27a
1991–2002 Resection 62 13 \0.0001 5 – 19 – 58
Nonresection 47
b 56 6 4 2
Beham et al.
21a 1993–2003 Resection 46 18 \0.001 4 – 7 – 85
Nonresection 21 8 0 0 38
Costi et al.
13a 1994–2003 Resection 83 9 \0.001
f 8 0.397 29 0.366 0
Nonresection 47 4 15 38
Law et al.
28a 1996–1999 Resection 150 7 \0.001 7 0.01 18 – 14
Nonresection 30 3 21 In total In total
Mik et al.
32a 1996–2000 Resection 52 21 NA – – 50 0.041 53.8
Nonresection 82 14 – 23.1 35.4
Stelzner
et al.
35a
1995–2001 Resection 128 11.4 \0.0001 12 0.784 NA – In total 99
Nonresection 58
c 4.6 10 NA
Asymptomatic only Resection 82 11.7 0.0002 9 0.401 NA – In total 99
Nonresection 25 5.2 4 NA
Yun et al.
37a 1994–2004 Resection 283 15.3 \0.001
g 3 – 3 – In total 56
Nonresection 93 5.3
Asymptomatic only Resection 95 15.1 0.072
g – – NA – In total 55
h
Nonresection 36 6.1 NA
Evans et al.
24 1999–2006 Resection 45 11 0.2056 16 – NA – –
Nonresection 52 7 36 NA
Aslam et al.
19 1998–2007 Resection 366 14.5 \0.005 7.6 – 32 – 63
Nonresection 281
d 5.83 NA NA 36
Frago et al.
38 2004–2008 Resection 12 39.1
e 0.008 8.3 – 41.6 – 100
Nonresection 43 1.0
e 6.1 11.1 86
a Study that concluded that resection should be performed if feasible
b Including 24 patients without intervention
c Including 16 patients without intervention
d A total of 168 patients received symptomatic and supportive treatment and 128 required surgical intervention
e Overall 2-year survival rate
f For patients with only technical resectable disease in both groups, also signiﬁcant
g Multivariate analysis
h Only chemotherapy was prognostic for OS in the asymptomatic group of patients
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were 7.3 times more likely to have a complication from the
primary tumor, and when operated for such complications,
they were more likely to have a poor postoperative
outcome.
33,39,42
In the United States, most patients with mCRC undergo a
resection of the primary tumor.
9 This is in contrast to the
situation in the Netherlands, where a trend toward a non-
resection approach has been observed.
43 This trend might
be due to the availability of new active drugs and to a more
adequate selection of patients for surgery.
44 Another argu-
ment in favor of resection of the primary tumor is the more
accurate staging of disease because extrahepatic metastases
may be better identiﬁed by visual exploration of the peri-
toneal cavity.
25,31 Circumstantial evidence comes from data
that show an increased growth rate of liver metastases on
resection of the primary tumor, as determined by an
increased vascular density, proliferation rate, and metabolic
growth rate.
45–47 These data suggest that the outgrowth of
metastatic disease may at least partly be controlled by the
primary tumor. However, clinical data to support this con-
cept are lacking. The most important argument against an
initial resection of the primary tumor is that the survival
beneﬁt of resection has not been demonstrated, and that the
morbidity and mortality associated with surgery should
therefore be avoided.
28,34,48 Poultsides et al.
49 concluded
that most patients with synchronous advanced CRC who
receive up-front systemic therapy never require palliative
surgery for their primary tumor, and that systemic therapy
can be safely administered to these patients. We challenge
their conclusion for two reasons. First, the median OS in
their patient population with intact primary was only
13 months, while median OS times of 22–24 months are
currently achieved for unselected mCRC patients. Second,
we observed a higher incidence of toxicity in the nonre-
section group compared to the resection group, especially in
TABLE 4 Studies in which resection was deﬁned as resection of primary tumor and nonresection was deﬁned as no intervention
Author Years of
study
Resection No. of
patients
OS
(months)
P value Postoperative
mortality (%)
P value Morbidity
(%)
P value Chemo
therapy (%)
Liu et al.
29a 1986–1991 Resection 57 11 NA 9 – 10 – –
Nonresection 5 2 NA NA
Ruo et al.
33a 1996–1999 Resection 127
b 16 \0.001 2 – 21 – –
Nonresection 103 9 NA NA 83
Kaufman et al.
26a 1998–2003 Resection 115 22 \0.0001 NA – NA – 51
Nonresection 69 3 30
Scoggins et al.
34 1985–1997 Resection 66 14.5 0.59 5 – 30 – –
Nonresection 23
b 16.6 NA NA 100
Tebbutt et al.
36 1990–1999 Resection 280 14 0.08
c NA – 13
d – 100
Nonresection 82 8.2 NA 13
d All in trials
Michel et al.
31 1996–1999 Resection 31 21 0.718 0 – NA – 97
Nonresection 23 14 NA NA 100
Benoist et al.
39 1997–2002 Resection 32 23 NA 0 – 19 – 100
b
Nonresection 27
b 22 NA 15
d 100
e
Galizia et al.
25a 1995–2005 Resection 42 15.2 0.03 0 – 21.4 – 100
Nonresection 23 12.3 100
Bajwa et al.
20 1999–2005 Resection 32 14 0.005 3 – 25 – 100
Nonresection 35 6 100
Chan et al.
22 2000–2002 Resection 286 14 \0.001 – – – – 61
Nonresection 125 6 – – 58
Evans et al.
24 1999–2006 Resection 45 11 \0.0001 16 – NA – –
Nonresection 57 2 NA NA
Seo et al.
23 2001–2008 Resection 144 22 0.076
c 0 – 34.7 – 100
Nonresection 83 14 100
a Study that concluded that resection should be performed if feasible
b Asymptomatic patients
c Multivariate analysis
d Obstruction primary tumor
e No differences in toxicity
3258 S. Venderbosch et al.the CAIRO2 study. Patients in the nonresection group
experienced more nausea, vomiting, and ileus, which might
be related to the primary tumor.
Scheer et al.
50 concluded that for patients with syn-
chronous metastatic disease and an asymptomatic primary
tumor, initial chemotherapy was the treatment of choice
because resection of the primary tumor provides only
minimal palliative beneﬁt, can give rise to major morbidity
and mortality, and therefore may delay potentially beneﬁ-
cial chemotherapy.
This possible detrimental effect of a delay in systemic
treatment caused by initial resection is not supported by the
survival beneﬁt, as shown in the CAIRO studies. However,
a selection bias in this respect cannot be excluded because
patients experiencing serious morbidity after resection
obviously did not qualify for the CAIRO entry criteria and
were therefore not included.
Taken together, the fact that the CAIRO results are
derived from clinical studies with predeﬁned inclusion
criteria, treatment regimens, and follow-up schedules in
our opinion provides stronger evidence for the prognostic
value of resection of the primary tumor in CRC patients
with stage IV disease compared with the data from the
studies as presented in our review. However, in all studies
presented to date, a selection bias cannot be excluded.
Therefore, prospective studies on this topic are warranted;
these are currently being planned.
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